IL2 and cancer: Recombinant IL-2 has been established as an anti-cancer drug (Waldmann 2006), but because of the dual function of both enhancing and downregulating immune responses, modified IL-2 with less specificity for Treg has been developed (Levin et al. 2012; Liao et al. 2013).